Back to Search Start Over

RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.

Authors :
Luca C
Pepe F
Pisapia P
Iaccarino A
Righi L
Listì A
Russo G
Campione S
Pagni F
Nacchio M
Conticelli F
Russo M
Fabozzi T
Vigliar E
Bellevicine C
Rocco D
Laudati S
Iannaci G
Daniele B
Gridelli C
Cortinovis DL
Novello S
Molina-Vila MA
Rosell R
Troncone G
Malapelle U
Source :
Personalized medicine [Per Med] 2022 Sep; Vol. 19 (5), pp. 395-401. Date of Electronic Publication: 2022 Jul 08.
Publication Year :
2022

Abstract

Aim: ALK , ROS1 , NTRK  and RET gene fusions and MET exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next-generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants. Materials & methods: In the present study, we report our NGS molecular records produced during a year of diagnostic activity. Results: Overall, our in-house developed NGS workflow successfully analyzed n = 116/131 (88.5%) NSCLC samples. Of these, eight (6.8%) and five (4.3%) out of 116 patients harbored ALK and RET gene rearrangements, respectively: one case harbored ROS1 gene fusion (0.7%). Conclusion: Our results highlight that an RNA-based NGS analysis can reliably detect gene fusion alterations, thereby playing a pivotal role in the management of NSCLC patients.

Details

Language :
English
ISSN :
1744-828X
Volume :
19
Issue :
5
Database :
MEDLINE
Journal :
Personalized medicine
Publication Type :
Academic Journal
Accession number :
35801400
Full Text :
https://doi.org/10.2217/pme-2022-0020